fibrinogen complex

Overview

The fibrinogen complex refers to the circulating plasma glycoprotein system centered on fibrinogen, a key component of hemostasis and thrombosis. In normal physiology, fibrinogen is converted by thrombin into fibrin, which polymerizes to form the structural basis of a blood clot. Because of this central role, fibrinogen is closely linked to coagulation, platelet aggregation, wound repair, and inflammatory responses.

Clinically, fibrinogen is widely used as a biomarker of coagulation status and systemic inflammation. Elevated fibrinogen is commonly associated with chronic inflammatory states and prothrombotic risk, while reduced levels may reflect consumption or impaired synthesis in severe illness or bleeding disorders. In recent biomedical research, fibrinogen has been examined in contexts ranging from acute ischemic stroke and severe trauma to COVID-19, Crohn's disease, polycystic ovary syndrome, and device hemocompatibility testing.

Recent Publications Summary (latest 30 papers)

Recent publications on fibrinogen complex focused mainly on its role as a biomarker of inflammation, coagulation, and thrombotic risk across diverse clinical settings. In children with nephrotic syndrome, serum fibrinogen was evaluated alongside urinary α1-microglobulin as a predictor of respiratory tract infection, with the study comparing affected children to healthy controls and using multivariate modeling to assess independent risk factors and combined prognostic performance 42402858Jul. In severe trauma, fibrinogen trajectories were examined together with platelet count and D-dimer to determine their value for predicting venous thromboembolism, reflecting interest in dynamic coagulation monitoring rather than single time-point measurement 42207594May. Fibrinogen was also assessed as part of a broader prothrombotic profile in middle-aged adults, where abdominal fat distribution measures were associated with sex-specific changes in fibrinogen and thrombin generation parameters 42131917May.

Several studies linked fibrinogen to inflammatory or disease-severity phenotypes. In severe COVID-19, fibrinogen was among the biomarkers significantly associated with coagulopathy, alongside leptin, IL-6, ferritin, neutrophil-lymphocyte ratio, C-reactive protein, erythrocyte sedimentation rate, and lactate dehydrogenase 42065184May. In smoking-induced COPD, fibrinogen was highlighted in a review of multi-omics biomarker detection as a reproducible circulating protein marker associated with disease severity, exacerbation risk, and mortality 41605376Jan. In polycystic ovary syndrome, serum fibrinogen was one of four proteins validated by ELISA after prior proteomic discovery, with ROC analysis used to evaluate diagnostic performance 42034305Apr.

Other publications examined fibrinogen in relation to therapeutic response or biomaterial engineering. In the RAISE trial subgroup analysis, baseline plasma fibrinogen levels were used to explore whether efficacy and safety differed between reteplase and alteplase in acute ischemic stroke treated within 4.5 hours of symptom onset 42089199May. A review of novel anticoagulant strategies discussed therapeutic targeting of fibrin or fibrinogen as part of approaches beyond direct oral anticoagulants, placing fibrinogen within the broader landscape of experimental anticoagulant and fibrinolytic development 41485707Jan. In tissue engineering, fibrinogen derivatives were used to create reinforced fibrillar network hydrogels by combining thrombin-driven fibrin assembly with light-activated covalent crosslinking of methacrylated fibrinogen, producing interpenetrating polymer network hydrogels with substantially increased viscoelastic moduli 42383387Jul.

What Changes, What Holds

1. Fibrinogen is emerging as a dynamic risk marker rather than a single static coagulation readout
METHOD Serial fibrinogen assessment is being used to improve prediction of thrombotic complications and infection risk, which sharpens the baseline biomarker role by emphasizing trajectories, combinations with other markers, and multivariable modeling rather than one-off measurement. That changes how fibrinogen is operationalized in practice and research, but it does not alter its established place as a marker of coagulation and inflammation. 42402858Jul42207594May

2. Fibrinogen remains a severity-linked inflammatory marker, with growing support for disease-specific prognostic use
REINFORCES These studies strengthen the existing view that fibrinogen tracks inflammatory burden and prothrombotic risk across illnesses such as severe COVID-19, COPD, and PCOS. The new work does not displace the baseline account; instead, it extends its clinical utility by supporting fibrinogen as part of multimarker panels and diagnostic discrimination in specific disease settings. 42065184May41605376Jan

3. Baseline fibrinogen levels may help stratify treatment response and biomaterial performance, but the established hemostatic role stands
NEW DIRECTION Reteplase-versus-alteplase subgrouping and fibrinogen-based hydrogel engineering move beyond the Overview’s biomarker framing into treatment stratification and materials design, areas the baseline does not cover. The stroke analysis suggests fibrinogen could inform thrombolytic choice, while the hydrogel work uses fibrinogen as a structural precursor rather than a circulating marker; neither finding overturns the hemostasis account, but both broaden its practical meaning. 42089199May42383387Jul

Overview update candidates: dynamic/trajectory-based fibrinogen monitoring for thrombotic risk; disease-specific prognostic use in severe COVID-19, COPD; and PCOS; treatment-stratification and biomaterial-engineering applications.